Literature DB >> 1500266

Phase II clinical study of pirarubicin in hormone resistant prostate cancer.

B L Rapoport1, G Falkson.   

Abstract

Twenty one patients with hormone resistant prostate cancer were entered in a phase II study of pirarubicin 70 mg/m2, as a single intravenous injection given at 21 day intervals. All patients had leukopenia (9 severe or life threatening) and 2 died of septicemia. Thrombocytopenia occurred in 5 patients (one life threatening) and anemia in 12 patients. One partial response of 3 months duration was documented. Pirarubicin 70 mg/m2 given intravenously at 21 day intervals causes severe hematological toxicity and has minimal therapeutic activity in patients with hormone resistant prostate cancer.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1500266     DOI： 10.1007/bf00873129

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  6 in total

1.  Phase I study of pirarubicin.

Authors:  A A Miller; M E Scheulen; U R Kleeberg; S Seeber; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

2.  Tetrahydropyranyl derivatives of daunomycin and adriamycin.

Authors:  H Umezawa; Y Takahashi; M Kinoshita; H Naganawa; T Masuda; M Ishizuka; K Tatsuta; T Takeuchi
Journal:  J Antibiot (Tokyo)       Date:  1979-10       Impact factor: 2.649

3.  A phase I study of 4'-0-tetrahydropyranyladriamycin. Clinical pharmacology and pharmacokinetics.

Authors:  K S Sridhar; T S Samy; R P Agarwal; R C Duncan; P Benedetto; A G Krishan; C L Vogel; L G Feun; N M Savaraj; S P Richman
Journal:  Cancer       Date:  1990-11-15       Impact factor: 6.860

4.  Response criteria for the prostate of the USA National Prostatic Cancer Project.

Authors:  G P Murphy; N H Slack
Journal:  Prostate       Date:  1980       Impact factor: 4.104

5.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

6.  Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy.

Authors:  D Dantchev; M Paintrand; M Hayat; C Bourut; G Mathé
Journal:  J Antibiot (Tokyo)       Date:  1979-10       Impact factor: 2.649
  6 in total
  2 in total

1.  Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin.

Authors:  S Naito; T Ueda; S Kotoh; J Kumazawa; K Itoh; K Sagiyama; T Omoto; S Andoh; Y Hasegawa; Y Fujisawa
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

2.  Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer.

Authors:  R M Mader; H Zilg; O Schlappack; G G Steger; M Baur; B Greifenberg; U Heberle; C Dittrich
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.